Skip to content

Atara Biotherapeutics, Inc.

ATRA

CIK 0001604464

← back to feed
Revenue (TTM)
$119.69M
−6.3% YoY Q1 May 2026
Net Income (TTM)
$31.95M
+138.3% YoY Q1 May 2026
EPS Diluted (TTM)
$3.08
+122.5% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
29.3%
Q1 May 2026
Net Margin
26.7%
Q1 May 2026
Free Cash Flow (TTM)
−$102.38M
Q1 May 2026
Cash
$8.36M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
9.01M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings